Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 26;18(4):466.
doi: 10.3390/ph18040466.

Enhancing Boron Neutron Capture Therapy (BNCT) with Materials Based on COSAN-Functionalized Nanoparticles

Affiliations

Enhancing Boron Neutron Capture Therapy (BNCT) with Materials Based on COSAN-Functionalized Nanoparticles

Albert Ferrer-Ugalde et al. Pharmaceuticals (Basel). .

Abstract

Background/Objectives: Boron neutron capture therapy (BNCT) is a promising approach for selectively targeting and destroying malignant cells using 10B isotopes. A significant challenge in BNCT lies in the development of efficient boron delivery systems that ensure adequate boron accumulation within tumor cells. This study aims to synthesize, characterize, and evaluate COSAN-functionalized nanoparticles (NP@I-COSAN) as a potential boron carrier for BNCT. Methods: Hybrid nanoparticles were synthesized by conjugating monoiodinated cobaltabisdicarbollides (I-COSAN) to commercially available acrylic polymer-based nanoparticles. Functionalization and cellular uptake were confirmed through FTIR, TGA, UV-Vis spectroscopy, and TEM/EDX analyses. Biocompatibility was evaluated by assessing cytotoxicity in HeLa cells and C. elegans as an in vivo model. Intracellular boron uptake was quantified using ICP-MS, with results compared to those obtained with 4-borono-L-phenylalanine conjugated to fructose (f-BPA). An in vitro BNCT proof-of-concept assay was also performed to evaluate therapeutic efficacy. Results: NP@I-COSAN demonstrated low cytotoxicity and efficient internalization in cells. ICP-MS analysis revealed stable boron retention, comparable to traditional boron agents. The BNCT assay further showed that NP@I-COSAN was effective in inducing tumor cell apoptosis, even at lower boron concentrations than conventional treatments. Conclusions: These results underscore the potential of NP@I-COSAN as an effective boron delivery system for BNCT, offering a promising strategy to enhance boron accumulation within tumor cells and improve treatment efficacy.

Keywords: BNCT; C. elegans; boron clusters; metallacarboranes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Representative scheme on the functionalization of NPs with I-COSAN, leading to the formation of NP@I-COSAN.
Figure 1
Figure 1
(A) Bar graphs indicating the percentage of HeLa cell survival after 24 h (left) and 48 h (right) of treatment with four different concentrations (10, 25, 50, and 100 μg∙mL−1) of NP@I-COSAN and the positive control (DMSO 10 vol. %), error bars mean ± 5%. (B) Fluorescence microscopy photographs of the LIVE/DEAD experiments of HeLa cells after being incubated for 24 h (left) and 48 h (right) with 100 μg∙mL−1 NP@I-COSAN.
Figure 2
Figure 2
TEM images of the accumulation of NP@I-COSAN inside HeLa cells after 48 h of incubation with solutions of 0.05 M of NP@I-COSAN.
Figure 3
Figure 3
In vivo evaluation of I-COSAN and NP@I-COSAN in the C. elegans model. (A) Optical microscope images of control and I-COSAN- and NP@I-COSAN-treated worms. The right pictures are insets with a higher magnification than the left image. The worm’s head and tail are highlighted in the left inset. Arrows indicate the presence of NP@I-COSAN. The scale bar on the right is 100 µm, and the scale bar on the left is 50 µm. (B) Biodistribution of NP@I-COSAN. Percentage of worms with NP@I-COSAN in each of the four parts (pharynx, anterior gut, central gut, and posterior gut). Each region was represented with a gradient color from 0 to 100%. (C) Survival rate after 24 h of incubation with S-basal buffer (control) and 25 µg/mL I-COSAN and NP@I-COSAN (N = 3, n = 150). (D) The length of the worms was evaluated after 24 h of nanomaterial exposure (N = 3, n = 50). * p < 0.05, ** p < 0.01.
Figure 4
Figure 4
Boron uptake in HeLa cells was evaluated after exposure to 0.045 ppm of 10B-NP@I-COSAN and 25 ppm of 10BPA-f for 2 and 4 h. (**) p < 0.01 and (***) p < 0.001, according to the two-way ANOVA analysis (Tukey’s test).
Figure 5
Figure 5
(A) Cell survival after treatment with 0.045 ppm of 10B-NP@I-COSAN and 25 ppm of 10BPA-f, post-neutron irradiation (2 Gy). (B) Dosimetry for thermal neutron irradiation without and with boron (25 ppm 10B). Note: Dosimetry for the BNCT groups is based on BPA-f, which has a boron-10 concentration of 25 ppm. (*) p < 0.05, according to the two-way ANOVA analysis (Tukey’s test).
Figure 6
Figure 6
(A) Quantitative analysis of fluorescence microscopy at 48 h post-irradiation; (B) Post-irradiation analyses of apoptotic and necrotic events (dead cells) were performed using fluorescence microscopy. Representative images of stained cells were taken 48 h after irradiation. Apoptotic nuclei, indicated by Hoechst staining (red arrows), exhibited features such as peripheral chromatin condensation, cytoplasmic blebbing, and fragmentation. The cytoplasm of viable cells was labeled with 4,5-diaminofluorescein (DAF), whereas necrotic cells were identified using propidium iodide (IP) staining (red arrows). (*) p < 0.05, (**) p < 0,01, (***) p < 0.001, according to the two-way ANOVA analysis (Tukey’s test).

Similar articles

References

    1. Gavas S., Quazi S., Karpiński T.M. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res. Lett. 2021;16:173. - PMC - PubMed
    1. Al-Thani A.N., Jan A.G., Abbas M., Geetha M., Sadasivuni K.K. Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review. Life Sci. 2024;352:122899. - PubMed
    1. Cheng Z., Li M., Dey R., Chen Y. Nanomaterials for cancer therapy: Current progress and perspectives. J. Hematol. Oncol. 2021;14:85. - PMC - PubMed
    1. Barth R.F., Vicente M.G., Harling O.K., Kiger W.S., 3rd, Riley K.J., Binns P.J., Wagner F.M., Suzuki M., Aihara T., Kato I., et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat. Oncol. 2012;7:146. - PMC - PubMed
    1. Marforio T.D., Carboni A., Calvaresi M. In Vivo Application of Carboranes for Boron Neutron Capture Therapy (BNCT): Structure, Formulation and Analytical Methods for Detection. Cancers. 2023;15:4944. doi: 10.3390/cancers15204944. - DOI - PMC - PubMed

LinkOut - more resources